Insights

Innovative Diagnostic Platform Selux Diagnostics has developed a Next Generation Phenotyping platform that significantly accelerates and enhances the accuracy of infectious disease diagnostics, presenting a compelling solution for healthcare providers seeking faster, targeted antibiotic treatments.

Strong Funding and Partnerships The company has secured substantial funding including a $48 million investment from Sands Capital Ventures and a $50 million Series C round, along with a strategic contract with BARDA, indicating robust financial backing and credibility with government agencies, ideal for scaling sales efforts.

Market Leadership Potential With its unique platform capable of delivering diagnostic results within a day, Selux is positioned to disrupt the infectious disease testing market and establish itself as a key player in combating antimicrobial resistance, creating opportunities to partner with major hospitals and health systems.

Growth and Expansion Opportunities Recent milestones include clinical trial funding and key hires, such as board members and executives, highlighting a company poised for growth and increased market penetration, suitable for collaborating on pilot programs or early adoption agreements.

Alignment with Public Health Goals Selux's focus on reducing hospital stays, fighting antibiotic resistance, and improving patient outcomes aligns with health system priorities and government initiatives, paving the way for partnership opportunities with hospitals, clinics, and public health agencies seeking innovative solutions.

Selux Diagnostics, Inc Tech Stack

Selux Diagnostics, Inc uses 8 technology products and services including TeamCity, SAP, jQuery Migrate, and more. Explore Selux Diagnostics, Inc's tech stack below.

  • TeamCity
    Continuous Integration
  • SAP
    Customer Relationship Management
  • jQuery Migrate
    Javascript Libraries
  • Linux
    Programming Languages
  • Python
    Programming Languages
  • HSTS
    Security
  • Google Tag Manager
    Tag Management
  • HTTP/3
    Web & Portal Technology

Media & News

Selux Diagnostics, Inc's Email Address Formats

Selux Diagnostics, Inc uses at least 1 format(s):
Selux Diagnostics, Inc Email FormatsExamplePercentage
FLast@seluxdx.comJDoe@seluxdx.com
96%
FMiddleLast@seluxdx.comJMichaelDoe@seluxdx.com
2%
FirstLast@seluxdx.comJohnDoe@seluxdx.com
1%
First@seluxdx.comJohn@seluxdx.com
1%

Frequently Asked Questions

Where is Selux Diagnostics, Inc's headquarters located?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc's main headquarters is located at 56 Roland St, Boston, Massachusetts, US. The company has employees across 1 continents, including North America.

What is Selux Diagnostics, Inc's phone number?

Minus sign iconPlus sign icon
You can contact Selux Diagnostics, Inc's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Selux Diagnostics, Inc's official website and social media links?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc's official website is seluxdx.com and has social profiles on LinkedInCrunchbase.

What is Selux Diagnostics, Inc's SIC code NAICS code?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Selux Diagnostics, Inc have currently?

Minus sign iconPlus sign icon
As of October 2025, Selux Diagnostics, Inc has approximately 51 employees across 1 continents, including North America. Key team members include Chief Financial Officer: M. H.Chief Financial Officer: J. P.Director Of Marketing: K. C.. Explore Selux Diagnostics, Inc's employee directory with LeadIQ.

What industry does Selux Diagnostics, Inc belong to?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc operates in the Biotechnology Research industry.

What technology does Selux Diagnostics, Inc use?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc's tech stack includes TeamCitySAPjQuery MigrateLinuxPythonHSTSGoogle Tag ManagerHTTP/3.

What is Selux Diagnostics, Inc's email format?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc's email format typically follows the pattern of FLast@seluxdx.com. Find more Selux Diagnostics, Inc email formats with LeadIQ.

How much funding has Selux Diagnostics, Inc raised to date?

Minus sign iconPlus sign icon
As of October 2025, Selux Diagnostics, Inc has raised $48M in funding. The last funding round occurred on Apr 01, 2024 for $48M.

When was Selux Diagnostics, Inc founded?

Minus sign iconPlus sign icon
Selux Diagnostics, Inc was founded in 2014.

Selux Diagnostics, Inc

Biotechnology ResearchUnited States51-200 Employees

Selux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. 

The CDC has cited bacterial resistance to antibiotics among the world’s deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. SeLux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected with multi-drug resistant organisms. 

Selux Diagnostics was founded in 2014 by two Yale- and Harvard-trained engineers working in an improvised attic laboratory. 

On September 25, 2018, SeLux announced that it had signed a milestone-based contract worth up to $45 million with BARDA, a division of the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system. 

SeLux has also raised $25 million in Series B financing to support the pivotal FDA trial for SeLux’s NGP platform. The round was led by Sands Capital Ventures and included returning investors RA Capital and Schooner Capital and new investors Sands Capital and Northpond Ventures.

Section iconCompany Overview

Headquarters
56 Roland St, Boston, Massachusetts, US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $48M

    Selux Diagnostics, Inc has raised a total of $48M of funding over 10 rounds. Their latest funding round was raised on Apr 01, 2024 in the amount of $48M.

  • $1M$10M

    Selux Diagnostics, Inc's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $48M

    Selux Diagnostics, Inc has raised a total of $48M of funding over 10 rounds. Their latest funding round was raised on Apr 01, 2024 in the amount of $48M.

  • $1M$10M

    Selux Diagnostics, Inc's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.